AstraZeneca Pharma India contests Rs 151.196 crore NPPA demand

AstraZeneca Pharma India Limited is contesting a National Pharmaceutical Pricing Authority demand of Rs 151.196 crore, including interest calculated through 30 October 2026, over alleged overcharging of a combination respiratory drug sold from May 2016 to November 2025. AstraZeneca Pharma India made no provision after interim court protection against coercive recovery until 11 January 2027.

What is the NPPA demand against AstraZeneca Pharma India?

The National Pharmaceutical Pricing Authority, or NPPA, directed AstraZeneca Pharma India to deposit Rs 148.658 crore, including interest, during the current financial year. The order alleges overcharging of a combination respiratory drug sold between May 2016 and November 2025, according to the notes to the unaudited results for the quarter and half year ended 30 September 2026.

A reminder notice dated 5 October 2026 sought Rs 151.196 crore, including interest calculated until 30 October 2026. That was Rs 2.538 crore above the Rs 148.658 crore in the earlier order. The filing does not identify the drug, separate principal from interest, or disclose the alleged overcharge by year.

Has AstraZeneca Pharma India provided for the NPPA demand?

AstraZeneca Pharma India made no provision for the Rs 151.196 crore NPPA demand in its financial statements for the half year ended 30 September 2026. Management said its assessment, supported by external legal advice, concluded that it has reasonable grounds to defend its position.

The Board approved the results on 5 November 2026, after the 5 October reminder notice and the High Court's 29 October 2026 order. The disclosed no-provision position therefore reflects management's assessment after those two events. The statutory auditors issued an unmodified limited-review conclusion on the half-year results.

The unprovided reminder amount exceeded both the Rs 62.33 crore profit after tax reported for the quarter ended 30 September 2026 and the Rs 100.16 crore reported for the half year. It was not recognised as an expense in the reported results because management's stated assessment was that it had reasonable grounds to contest the claim.

What protection has the High Court given AstraZeneca Pharma India?

The High Court directed on 29 October 2026 that the NPPA should take no coercive steps to collect the demanded amount until the next hearing. AstraZeneca Pharma India had filed a writ petition, and the matter is listed on 11 January 2027.

The 29 October direction is interim protection from coercive collection rather than a disclosed final finding on the alleged overcharging. The filing does not say that the Rs 151.196 crore demand was cancelled, reduced or permanently stayed. It specifies only that coercive recovery cannot proceed until the next listed hearing on 11 January 2027.

The scheduled January 2027 hearing is the next disclosed event in the dispute. AstraZeneca Pharma India did not forecast the court's decision or disclose whether the NPPA might revise its claim further as interest continues to be calculated after 30 October 2026.

How does the NPPA matter compare with AstraZeneca Pharma India’s results?

AstraZeneca Pharma India reported revenue from operations of Rs 729.10 crore for the quarter ended 30 September 2026, compared with Rs 559.09 crore a year earlier. Profit after tax rose to Rs 62.33 crore from Rs 54.22 crore, while the NPPA claim was not recorded as a provision.

For the half year ended 30 September 2026, revenue from operations increased to Rs 1,411.89 crore from Rs 1,085.40 crore in the prior-year period. Profit after tax declined to Rs 100.16 crore from Rs 110.05 crore. AstraZeneca Pharma India identifies healthcare as its only reportable segment under Indian Accounting Standard, or Ind AS, 108, so it disclosed no separate revenue or profit for respiratory drugs.

Cash and cash equivalents stood at Rs 573.81 crore on 30 September 2026, compared with Rs 447.72 crore on 31 March 2026. Total assets were Rs 2,191.40 crore and total equity was Rs 878.92 crore at 30 September 2026. These reported balance-sheet figures do not alter the stated no-provision accounting treatment for the NPPA claim.

How does the NPPA treatment differ from the BBMP provision?

AstraZeneca Pharma India recorded exceptional items of Rs 14.96 crore for the September 2026 quarter and Rs 15.20 crore for the first half. The notes say these items included interest related to Bruhat Bengaluru Mahanagara Palike, or BBMP, improvement charges and costs associated with closing the Bangalore manufacturing site.

The company had recognised a Rs 7.08 crore provision in earlier years for BBMP improvement charges on factory land. During the current period, it recognised Rs 15.61 crore of interest provision after the final Karnataka High Court judgment and said it intended to settle that matter. Management described the amount as its current estimate of a probable outflow, subject to reassessment after ultimate determination.

The treatment differs from the NPPA dispute because AstraZeneca Pharma India recognised the BBMP interest provision but did not provide for the Rs 151.196 crore NPPA reminder amount. The company cited its assessment and external legal advice for the NPPA position, whereas it said it intended to settle the BBMP matter after recognising Rs 15.61 crore of related interest.

Conclusion

AstraZeneca Pharma India disclosed an NPPA claim of Rs 151.196 crore that exceeds its Rs 100.16 crore half-year profit after tax, yet has not recorded an expense or provision for it. The company’s separate treatment of the Rs 15.61 crore BBMP interest provision shows that management has made different assessments of the two regulatory matters disclosed in the September 2026 results.

The next disclosed milestone is the High Court hearing on 11 January 2027. Investors will need to watch for any court direction, a further NPPA notice that changes the amount beyond interest calculated to 30 October 2026, or a revised management assessment that changes the no-provision position in later financial statements.